Sintilimab

Generic Name: Sintilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tucidinostat
Drug: Fruquintinib
Drug: Sintilimab
Drug: Bevacizumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-12-03

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 430

Registration Number: NCT06497985

Locations: 🇨🇳
Rui-Hua Xu, Guangzhou, Guangdong, China

Induction IBI110 and Sintilimab With Chemotherapy In LA HNSCC

Phase 1

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: Sintilimab
Drug: IBI110
Drug: Paclitaxel
Drug: Cis Platinum
Procedure: Surgery
Radiation: Adjuvant radiation

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06494943

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Phase 2

Conditions: Gastric Cancer Peritoneal Metastases

Interventions: Drug: albumin-bound paclitaxel (260 mg/m2, d1)
Drug: S-1
Drug: sintilimab
Drug: bevacizumab

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 42

Registration Number: NCT06487715

Locations: 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2024-06-18

Last Posted Date: 2024-06-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06463834

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC

Active, not recruiting

Conditions: HCC
Recurrence
Immunotherapy
Adjuvant Therapy

Interventions: Drug: Sintilimab
Drug: Lenvatinib

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: Chen Xiaoping

Target Recruit Count: 620

Registration Number: NCT06461936

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, Hubei, China

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Not Applicable

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Drug: Sintilimab
Drug: NAs
Drug: Peg-IFNα-2b

First Posted Date: 2024-06-13

Last Posted Date: 2024-06-20

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 50

Registration Number: NCT06457477

Locations: 🇨🇳
the Fifth Medical Center, Chinese PLA General Hospital, Beijing, Beijing, China

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
Gastro Esophageal Junction Cancer

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06447636

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Phase 1

Recruiting

Conditions: Leptomeningeal Metastasis
NSCLC
PD-1 Inhibitor
Low Dose Radiotherapy

Interventions: Radiation: Whole Brain Low Dose Radiotherapy
Drug: Pemetrexed
Drug: Sintilimab
Drug: Chemotherapy

First Posted Date: 2024-05-28

Last Posted Date: 2024-05-28

Lead Sponsor: Sichuan University

Target Recruit Count: 10

Registration Number: NCT06431685

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Phase 2

Recruiting

Conditions: Lung Cancer

Interventions: Drug: Tafolecimab
Drug: Sintilimab
Drug: Nab paclitaxel
Drug: Docetaxel
Drug: Gemcitabine

First Posted Date: 2024-05-20

Last Posted Date: 2024-05-20

Lead Sponsor: Jinghui Wang

Target Recruit Count: 30

Registration Number: NCT06421298

Locations: 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Sintilimab
Chemoradiotherapy
Elderly Patients
Esophageal Cancer
Immunotherapy

Interventions: Drug: Sintilimab

First Posted Date: 2024-05-14

Last Posted Date: 2024-07-16

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 191

Registration Number: NCT06413342

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy